Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased …
CW Ockeloen, A Raaijmakers… - Journal of Oncology …, 2023 - journals.sagepub.com
Decreased dihydropyrimidine dehydrogenase enzyme activity is associated with severe
fluoropyrimidine-associated toxicity. Four clinically relevant variants in the DPYD gene are …
fluoropyrimidine-associated toxicity. Four clinically relevant variants in the DPYD gene are …
Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study
C De Metz, B Hennart, E Aymes, PY Cren… - Cancer …, 2024 - Wiley Online Library
Abstract Introduction In April 2019, French authorities mandated dihydropyrimidine
dehydrogenase (DPD) screening, specifically testing uracilemia, to mitigate the risk of …
dehydrogenase (DPD) screening, specifically testing uracilemia, to mitigate the risk of …
Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients
M Pinheiro, A Peixoto, P Rocha, C Santos… - Pharmacogenetics …, 2023 - journals.lww.com
Objectives Genetic variants in the dihydropyrimidine dehydrogenase (DPYD) gene are
associated with reduced dihydropyrimidine dehydrogenase enzyme activity and can cause …
associated with reduced dihydropyrimidine dehydrogenase enzyme activity and can cause …
Developing DPYD Genotyping Method for Personalized Fluoropyrimidines Therapy
BYL Wong, Z Li, MJ Raphael… - The Journal of …, 2024 - academic.oup.com
Background Fluoropyrimidine drugs are widely used in chemotherapy to treat solid tumors.
However, severe toxicity has been reported in 10% to 40% of patients. The DPYD gene …
However, severe toxicity has been reported in 10% to 40% of patients. The DPYD gene …
[HTML][HTML] Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients
E Gross, B Busse, M Riemenschneider, S Neubauer… - PloS one, 2008 - journals.plos.org
Background Cancer patients carrying mutations in the dihydropyrimidine dehydrogenase
gene (DPYD) have a high risk to experience severe drug-adverse effects following …
gene (DPYD) have a high risk to experience severe drug-adverse effects following …
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
MJ Deenen, D Meulendijks, A Cats… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Fluoropyrimidines are frequently prescribed anticancer drugs. A polymorphism in
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …
[HTML][HTML] Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door
MDS Donadio, DM Carraro, GT Torrezan… - …, 2022 - ncbi.nlm.nih.gov
Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) genes is
gaining importance as predictors of fluoropyrimidine-associated toxicity. The …
gaining importance as predictors of fluoropyrimidine-associated toxicity. The …
DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview
NH Paulsen, F Vojdeman, SE Andersen… - Basic & Clinical …, 2022 - Wiley Online Library
Background In clinical oncology, systemic 5‐fluorouracil (5‐FU) and its oral pro‐drugs are
used to treat a broad group of solid tumours. Patients with dihydropyrimidine …
used to treat a broad group of solid tumours. Patients with dihydropyrimidine …
Clinical relevance of DPYD variants c. 1679T> G, c. 1236G> A/HapB3, and c. 1601G> A as predictors of severe fluoropyrimidine-associated toxicity: a systematic …
D Meulendijks, LM Henricks, GS Sonke… - The Lancet …, 2015 - thelancet.com
Background The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …
DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events
M de With, G Brufau, LA van den Berg… - JCO Precision …, 2022 - ascopubs.org
PURPOSE Around 20%-30% of patients treated with fluoropyrimidines develop severe
treatment-related adverse events (AEs). These are mainly caused by deficiency of …
treatment-related adverse events (AEs). These are mainly caused by deficiency of …